Gland Pharma Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Q4FY26 Audited Financial results".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.4 pts more than Nifty Smallcap 250 and 16.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma reported record Q4 FY26 results with consolidated revenue of ₹17,428 million, up 22% YoY, and adjusted PAT of ₹3,667 million, surging 97% YoY. The company achieved an adjusted EBITDA margin of 30% in Q4, up from 24% in Q4 FY25. For the full year FY26, revenue grew 14.5% to ₹64,307 million with PAT up 50% to ₹10,455 million. The CDMO (contract manufacturing) segment contributed 46% of revenues and grew 36% YoY in Q4. The Board recommended a final dividend of ₹20 per share. The company launched 31 products in the US during FY26 and filed 24 ANDAs.
Strong Q4 results with near-doubling of PAT and margin expansion signal operational efficiency improvements and robust CDMO momentum. The dividend announcement and 22% revenue growth are positive signals for shareholders, though investors should monitor the relatively low EBITDA performance at Cenexi subsidiary (1% margin in Q4).